REQUEST A DEMO
Total
USD $0.00
Search more companies

UAB Gl Pharma Vilnius (Lithuania)

Main Activities: Research and Development in the Social Sciences and Humanities | Advertising Agencies | Marketing Research and Public Opinion Polling
Secondary Activities: Advertising Agencies
Full name: UAB Gl Pharma Vilnius Profile Updated: January 01, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Russian Download a sample report

UAB Gl Pharma Vilnius is based in Lithuania. The head office is in Vilnius. The company operates in the Research and Development in the Social Sciences and Humanities industry. It was first established on November 30, 2006. It currently has a total number of 6 (2025) employees. The company’s latest financial report indicates a net sales revenue increase of 34.74% in 2024. The enterprise’s net profit margin increased by 5.06% in 2024.

Headquarters
A. Jaksto g. 12
Vilnius; Vilnius county; Postal Code: LT-01105

Contact Details: Purchase the UAB Gl Pharma Vilnius report to view the information.

Basic Information
Total Employees:
Purchase the UAB Gl Pharma Vilnius report to view the information.
Registered Capital:
Purchase the UAB Gl Pharma Vilnius report to view the information.
Financial Auditors:
Purchase the UAB Gl Pharma Vilnius report to view the information.
Incorporation Date:
November 30, 2006
Key Executives
Purchase this report to view the information.
Director
Company Performance
Financial values in the chart are available after UAB Gl Pharma Vilnius report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency EUR. Absolute financial data is included in the purchased report.
Net sales revenue
34.74%
Total operating revenue
34.74%
Net Profit (Loss) for the Period
719.96%
Total Equity
37.56%
Net Profit Margin
5.06%
Return on Equity (ROE)
22.72%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?